Home > Cardiology > Transcatheter valve-repair system promising against tricuspid regurgitation

Transcatheter valve-repair system promising against tricuspid regurgitation

Journal
The Journal of the American College of Cardiology
Reuters Health - 04/02/2021 - Ongoing research suggests it is feasible to use the PASCAL transcatheter valve-repair system to treat patients with severe symptomatic tricuspid regurgitation (TR). The condition is increasingly prevalent and reduces both survival and quality of life, said Dr. Susheel Kodali of Columbia University Medical Center in New York City. "Surgery for tricuspid regurgitation remains a highly morbid surgery with significant mortality risk," he told Reuters Health by email. "There is no approved transcatheter therapy for TR, but several devices including PASCAL have shown promise in early studies in reducing TR and improving clinical symptoms with a much less morbid procedure than surgery." In a new paper in the Journal of the American College of Cardiology, Dr. Kodali and his colleagues report 30-day results from 34 enrolled patients. Their average age was 76 years, 88% had atrial fibrillation/flutter and 94% had systemic hypertension. Oth...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on